Key elements of the existing regulatory approach, such as the supervision of notified bodies, risk classification, conformity assessment procedures, performance evaluation and performance studies, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding in vitro diagnostic medical devices should be introduced, to improve health and safety.
Ba cheart príomheilimintí den chur chuige rialála atá ann faoi láthair, amhail maoirseacht ar chomhlachtaí dá dtugtar fógra, aicmiú riosca, nósanna imeachta um measúnú comhréireachta, meastóireacht feidhmíochta agus staidéir feidhmíochta, aireachas agus faireachas margaidh, a neartú go mór, agus ba cheart forálacha lena n-áiritheofar trédhearcacht agus inrianaitheacht maidir le feistí leighis diagnóiseacha in vitro a thabhairt isteach chun an tsláinte agus an tsábháilteacht a fheabhsú.